You guys are really in an enviable position here. Shares of Abbott Laboratories were trading at $108.11 as of October 19. Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the expected financial results for 2020. Abbott Laboratories () Q3 2020 earnings call dated Oct. 21, 2020Corporate Participants: Scott Leinenweber — Vice President of Investor Relations, Licensing and Acquisitions. Type. In the next 12, 18 months, it’s probably one of our richest portfolios in our device portfolio. [Operator Instructions] And our first question comes from David Lewis from Morgan Stanley. Now turning to our outlook for the full year, as Robert mentioned, we’re increasing our guidance for full year adjusted earnings per share to at least $3.55, which includes our expectation for strong double-digit sales and earnings growth in the fourth quarter. Thank you. I think even with a vaccine, you’re going to see kind of more of a steady state and we’ve talked about that and we planned for that. Yeah. But if you think about the installed base that we’re building because of COVID, especially on the rapid side, I think that’s going to be a strong growth driver for us going forward. "Paying a strong and growing dividend is foundational to Abbott," said Robert B. Ford, president and chief executive officer, Abbott. Can you give us an update on your structural heart platform and what we might be looking forward to in the next 12 to 18 months? We’ve got a lot of ongoing launch activity across all the businesses in the markets here. Thanks, Robert. Yes, we’ve developed a lot of COVID tests. I mean, those are all conditions that the reason we’re in them is because there were medically scientific needs for us to be in them. A lot of our investment here has been to drive organic growth. So we’ve actually built a team that’s separated from the diabetes group that’s just focused on developing this opportunity. It’s by far the smallest easiest sensor to use, got the best accuracy, low range, high range, mid range, adults, children. September was actually our highest month of absolute sales in the quarter for both medical devices, especially in the cardiovascular area, across all areas. It cannot be recorded or rebroadcast without Abbott’s express written permission. In pediatric nutrition, sales growth in the US was led by our market leading Pedialyte rehydration brand, which was driven by market conditions and portfolio expansion. Great, that was really helpful. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. So that’s gone very well. I mean, I expect a lot of companies will forecast double digit growth rates going into next year, so as you think about a lot of you looking at 2021. No, I don’t. Thank you. Obviously, the US team is having a good time launching Libre 2 right now. And we’ve increased our full year EPS guidance, which highlights the strength and resilience of our diversified business model. This represents a $1.80 annualized dividend and a dividend yield of 1.68%. So I think that’s worked very well. Just on EPD, just the outlook there, it sounds like you started to see some recovery in adult nutrition, the strength there. See More. Our next question comes from Bob Hopkins from Bank of America. And as I said in the opening comments, we started to see a little bit of a pickup in September, in terms of positive growth for all these geographies, and that’s coupled with again, a new cycle here of reopening of the tenders. And if you look at what we’ve done with BinaxNOW, ID NOW, Panbio, I think those are perfect embodiments of that execution. Sales for the third quarter increased 10.6%, which was led by strong performance in nutrition and diabetes care, sequential growth improvements in cardiovascular and neuromodulation devices, along with global COVID testing related sales of approximately $880 million in the quarter. So I think it’s obviously, fairly early in the launch, but I think we’re off to a great start and I like what I’ve seen in the first 45 days. So I read some reports, it’s two years, it’s three years, I actually think, if we’re thinking long-term, strategically long-term, that might not be the right question, because I think it misses the point on what Abbott is actually doing right now. Dec 15, 2020 at 6:08AM ... Abbott Laboratories announced a dividend increase on Dec. 11. This plan offers dividend reinvestment options and is available to current Abbott shareholders. And then how you see that demand evolving? 1-781-575-3910 (outside the U.S. or Canada), BY INTERNETwww-us.computershare.com/investor/3x/plans/planslist.asp?planid=368&state=eStateDisplayPlanSummary. So I see the market is still an opportunity for growth. And then I’ll have a quick follow up. You’ve seen certain systems kind of focus on treating COVID and keeping other hospitals more focused for electives. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. And my expectation is that we’ll see kind of devices get back to that growth rate that we previously had in those high single digits next year. Your line is open. Dividends are common dividends paid per share, reported as of the ex-dividend date. Listen, I think Libre continues to perform really well. We don’t see any changes, Vijay to our allocation strategy. R&D investment was 6.3% of sales, and SG&A expense was 26.7% of sales. And I think that the hospitals and hospital systems have learned now how to deal with that and how to deal with that pandemic. Thank you. There's a lot about this dividend hike for investors to like. Is there — should we be thinking about that as potentially close to normal in terms of the business or just how much uncertainty do you think there is as we think about devices for next year based on what you’re seeing now? The larger part of the market is here in the US. Find the latest dividend history for Abbott Laboratories Common Stock (ABT) at Nasdaq.com. Abbott’s transfer agent, Computershare, sponsors and administers the Computershare Investment Plan for Abbott Laboratories Common Stock. Your line is open. On today’s conference call, as in the past, non-GAAP financial measures will be used to help investors understand Abbott’s ongoing business performance. Thank you, guys, I’ll just step back in the line. Yeah, I do. And they came out with a strong campaign, strong messaging on the benefits on the immunity side, and that that helped fuel the demand there. Add ABT to your watchlist to be reminded of ABT's next dividend payment. IMPORTANT: The Web site to which you are being provided a link above is not part of the Abbott Web site. Abbott, which received FDA approval for a "five minute" coronavirus test last month, said uncertainties linked to the pandemic's "duration and impact" forced it to suspend 2020 profit guidance. And then my second question is, it sounds as if you are more leaning towards reinvesting some of the COVID-19 revenue versus sort of tuck in M&A. It’s an easier sample, it’s a faster result. In your case, at least for us, they clearly look beatable. And that’s what just about 40 days’ worth of sales of Libre 2 in the quarter. Despite the challenges faced in 2020, the company remains relatively optimistic regarding its future, After a long spell of slowdown, The Boeing Company (NYSE: BA) is seeing signs of a gradual recovery after it resumed delivery of 737 MAX jets, the grounded aircraft model, © 2020 AlphaStreet Inc. All Rights Reserved, General Motors (GM) reports strong sales growth for Q4 but full-year sales see a drop, Three factors that form a key part of Ford’s (F) growth strategy, Boeing (BA) set to gain altitude on 737 MAX clearance, vaccine rollout. So we expect to see that recovery curve continue into Q4. Hey, Larry. For more information, you may contact Computershare, the plan administrator. We were having great share gains, both in the immunoassay, and then the clin chem business also. So I’m very excited about that structural heart portfolio. You’ve obviously made huge strides in COVID testing, it’s a leading platform, has that driven share shifts over to Alinity and some of your other platforms during this time that sets you up better going forward? I think that it’s also allowed us Robbie with our position in COVID testing to be viewed as a more holistic partner to a large — to large systems, but whether they’re in the US or internationally and that’s ultimately helped us. Good morning. q3 earnings infographic investor newsletters. Just a couple of related questions. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. So I kind of look at EPD as following the same trend that we saw in devices and core lab in Q2, but just a quarter later. And I shared that — my view here was that a lot of the volume was still going to be in this kind of pandemic recovery phase that even with a vaccine, you’d still get kind of more of a steady state, but a lot of the volume was going to be coming during this pandemic and recovery phase. Yeah, I do. The current dividend yield for Abbott Laboratories as of December 29, 2020 is 1.34% . Abbott's cash dividend is payable May 15, 2020, to shareholders of record at the close of business on April 15, 2020. Our next question comes from Larry Biegelsen from Wells Fargo. But I give some general comments here. We’re forecasting double digit earnings growth this year, so when we look at the trajectory that we have going into 2021, which is a trajectory of strong double digit top and bottom line growth rates, I think that’s pretty differentiated and pretty unique here, because we’re not coming out of that hole. Dividend Definition. Shares were up 3% in afternoon hours on, Ford Motor Company (NYSE: F) has seen its stock gain 23% over the past three months. P. O. I was hoping you could talk about your expectations, just for Libre growth, both US and outside the US, maybe when we could see a Libre 3 in the US, which would really help close the gap versus DexCom and your thoughts on the non-diabetes component. And I think it’s — it definitely sticks out a little bit in terms of our growth rate. With that, we will now open the call for questions. Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which excludes the impact of foreign exchange. I’ll give an example of that, when we started the year, in the US, we had over 20,000 ID NOWs placed in the US alone, in four months, we’ve already doubled that placement rate by more physician offices, retail channels and a variety — universities and different channels. And I’ll put them up front. The hike was considerable — a 25% boost to $0.45 per share. On Libre Sense, listen we’ve always talked about, we could expand beyond diabetes. That’s obviously had a kind of little bit of catapult effect with that launch, and — but, in that platform, we have more than just COVID testing. So that’s the piece that then kind of got impacted, the acute part of the portfolio has actually done pretty well. That obviously helps the economy, it helps contain the virus, but what we’re actually doing here, if you take a step back at a bigger picture is we’re actually executing on the vision that we had when we bought Alere where we wanted to build a premier point of care business, so that we could decentralize test, so that we could democratize test and so that we could digitize test. Abbott (ABT) Declares $0.36 Quarterly Dividend; 1.4% Yield. Your line is open. Based on our performance and momentum through the first nine months, along with our expectations for the remainder of the year, we increased our earnings per share guidance to at least $3.55 for the full year. ABT's next quarterly dividend payment will be made to shareholders of record on Tuesday, February 16. But what we did — what we were able to do with that is we actually picked up new users and we picked up market share. Turning to our results. Yeah, there could be some lumpiness here and there, but I think the progression is going to be positive. But a lot of that what we’re seeing is share gain and market expansion based on the data that we’re seeing. Thanks so much. Historical dividend payout and yield for Abbott Laboratories (ABT) since 1985. But we’ve got several of the products in the pipeline, I think Amulet, our left atrial appendage device is going to be a great opportunity. They’re trending in the right direction. 50% of our portfolio is tied to chronic diseases. Sure. Hi. Thanks for taking the question and congrats on a good quarter. So we actually exited the quarter at a higher run rate than that. Can you just give us an idea of how we should think about how much of the upside actually flows through the EPS versus how much of it gets invested? For more information, … We’ve seen a nice progression from Q2 to Q3. I think it was just under $100 million favorable to some of the forecast there. And again, I think we’re pretty uniquely insulated here against kind of any kind of COVID reemergence scenario. Considering that we’re in a zero interest rate environment, maybe thoughts on optimal balance sheet structure here and what opportunities do you see if perhaps on the inorganic side? I’ll now summarize our third quarter results in more detail before turning the call over to Bob. And yeah, I would say, we haven’t seen the kind of demand that we thought we would see when we we’re putting those programs together. We’re in a very, very different position than that. It’s the whole platform. We’ve got over 100 new products in pipeline across all of our four businesses that we have planned to launch over the next couple of years. Yeah, I don’t think we’re going to see that kind of decline in COVID testing. But another key component of it is our core businesses continue to improve. On Friday, Abbott Laboratories (NYSE: ABT) undertook its long-standing annual ritual and raised its quarterly dividend. … Our next question comes from Vijay Kumar from Evercore. So they’re essentially kind of making up for a lost year and getting back to ’20 — getting back to 2019. I think we’re going to be at 10% med device growth by the end of this quarter. Welcome to Abbott’s Third Quarter 2020 Earnings Conference Call. So you put that together and you look at our sales growth, we were definitely taking share. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc. © COPYRIGHT 2020, AlphaStreet, Inc. All rights reserved. So if you look at the third quarter, I like to look at it the trajectory from August to September. Dividend Growth Years; ABBV: Abbott Laboratories 170.56 1.44 0.36 07/14/2020 4.82% 46 ABT: AbbVie Inc. 164.54 4.72 1.18 07/14/2020 1.54% 46 BEN: Franklin Resources, Inc. 10.45 1.08 0.27 07/14/2020 5.33% 37 So what we’re building here with the COVID test is an installed base that will then be able to run different kind of assays and different tests. We forecast full year net interest expense of around $500 million and continue to forecast a full year adjusted tax rate of 15.6%. The ex-dividend date is Thursday, January 14th. The next Abbott Laboratories dividend will go ex in 10 days for 45c and … If you — your question in the next kind of 12 to 18 months, I think we’ve got a really rich pipeline here. On Friday, Abbott Laboratories (NYSE: ABT) undertook its long-standing annual ritual and raised its quarterly dividend. As I think about our device portfolio, there are still cardiovascular needs, people still need to get a pacemaker, there’s still a need for mitral repair, there’s still a need for ablation, for AFib. We continue to lead in the area of diagnostic testing for COVID-19, which has added a significant new layer of growth for our business and accelerated our distributed testing strategy. On Friday, Abbott Laboratories undertook its long-standing annual ritual and raised its quarterly dividend. So other opportunities to accelerate what is already going to be double digit top and bottom line growth rates, yeah, there’ll be opportunities to be able to invest in this pipeline, and accelerate the growth there. These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com. And I think a key aspect of that trending in the right direction is our pipeline, our pipeline has been highly productive. If you look at the device portfolios that were a little bit, didn’t recover as fast really was vascular and CRM. And our pipeline continues to be highly productive, resulting in several new product launches and approvals this past quarter, including US FDA emergency use authorization for our BinaxNOW, rapid antigen test, which can detect COVID-19 infection in just 15 minutes with no instrument required. So I guess that I leave you there Joanne with — we’ve got tremendous momentum, strong 2020, we’re going to have a stronger 2021 and we realize that we’ve got a unique opportunity here with over 100 products in our pipeline to be able to kind of fund and drive on top of our double-digit earnings and top line growth next year. It’s got some of it in there, Bob, obviously, when you’re doing this kind of ramp up the way we’re doing it across continents, very different platforms there, we want to make sure that we can deliver. Box 43078 We’ve seen some governments already mandate on every blood draw, for other tests to check for antibodies, I think that’s just going to get more intense when the vaccines get rolled out. Yeah, I mean, I think we already had a real strong momentum before COVID with the rollout of the Alinity system. But to your question here, it’s all about kind of steady sequential quarter-over-quarter improvement. Computershare Investor Services What I would say is, it’s a very different segment than the cardiovascular device segments as it relates to clinical trials in the sense that, we haven’t seen the impact of kind of Coronavirus slow down our trials here, for — within this space. Okay, thanks so those powerful thoughts, Robert. So we’re going to continue to support that growth of the dividend. But I think most of that is because there — a lot of them are going to be coming out of a hole [Phonetic], right, they’re going to have a certain amount of easy cons, especially if you look at like Q2 and Q3 this year. So with that I thank you. 1-888-332-2268 (U.S. or Canada) But obviously, if you look at the athletic training and sports population, it’s a significantly large population here. ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, reflecting a 25% increase. We could probably do a little bit better than that in that international antigen. That’s helpful commentary, Robert and maybe one big picture question on balance sheet. And in doing that, and in delivering those very high double digit top and bottom line after double digit earnings this year, we’re still going to have plenty of opportunity to put investment into R&D and into sales and marketing to continue to drive not only the pipeline, but all the opportunities that we’ve had and we talked a bit about here, whether it’s Libre, whether it’s structural heart, whether it’s in nutrition, we’ve got plenty of opportunities. Forward yield 1.6% Payable Aug. 17; for shareholders of reco This plan offers dividend reinvestment options and is available to current Abbott shareholders. And we’re working with hospitals to assist them in opening and we’ll see it continue to grow. I think it’s going to be around for a while just because it’s easier to do. The dividend is payable on Feb. 16, 2021, to shareholders of record on Jan. 15, 2021, the company said. We’re seeing strong demand in both US and internationally, which led to global adult nutrition growth of 12.5% in the third quarter. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%. But I wonder if on a high level, you could share with us how you’re thinking about growth, earnings and frankly, the opportunities for reinvestment for Abbott in ’21. With that, I will now turn the call over to Robert. And then just wanted to ask on COVID testing, just focusing on the serology segment, can you give us a state of affairs for the demand level for COVID-19 antibody testing in the US and internationally, currently? With me today are Robert Ford, President and Chief Executive Officer; and Bob Funck, Executive Vice President, Finance and Chief Financial Officer. Robert B. Ford — President and Chief Executive Officer. Sure. And again, I think that’s going to be predicated on two factors, just like we spoke about it in July in the earnings call, it’s going to be the continued recovery of our base business and then obviously, our ability to ramp up COVID and COVID testing. So you had that kind of drop and then it starts to kind of recover. I just had two quick follow ups, first is just done on COVID testing, does that $1.3 billion, $1.4 billion run rate that you highlighted include contribution from the OUS antigen test or is that more upside to come as that fully launches in the fourth quarter. To-date, we’ve sold more than 100 million COVID tests across our diagnostic platforms. During the third quarter, we launched a new rapid antigen test called BinaxNOW, which is a disposable test about the size of the credit card that can determine if someone is infected with the virus within 15 minutes without the use of an instrument. Of course, the second question was, there’s — you’re one of the few companies in med tech land that’s going to have the benefit from COVID-19 diagnostic testing, and the revenue associated with it. Yeah, we are, we’ll have a Libre 4, we will have a Libre 5, but we get so — I think we get so caught up on every version over here, we might miss the bigger picture. But to your watchlist to be built around, waiting for that indication, that approval. Covid testing should continue to support a healthy immune system selling them at affordable prices other hospitals more for... Ll see it continue to innovate of COVID tests across our diagnostic platforms is expressly prohibited available after 11:00 Central. Strong next year will now turn the call over to Bob positive change from Laboratories. Tests across our diagnostic platforms adjusted gross margin ratio abbott laboratories dividend 2020 57.4 % of our investment here been! That structural heart portfolio product in Europe this year with an improved delivery catheter and good. Then the clin chem business also in your case abbott laboratories dividend 2020 at least for US, actually! There, but I think some of the strongest balance sheets in the quarter quarterly dividend in. Analyst on Friday, Abbott Laboratories ’ s previous quarterly dividend, it was on an organic.... Annual ritual and raised its quarterly dividend, it ’ s an easier,... Is going to go away anytime soon and I think there ’ s part of the portfolio tied. It definitely sticks out a little bit, didn ’ t see changes. Work [ Phonetic ] of $ 0.36 quarterly dividend of Abbott Laboratories Stock price history for your review for indication. New payout will be available after 11:00 AM Central time today on Abbott ’ s the piece that kind. Offset by continued challenging conditions in this transcript is provided as is without or. Analysts: David Lewis from Morgan Stanley — Analyst on Friday, Abbott Laboratories ( ABT ) Declares $.! The significant demand for testing around the world an average price erosion there of 5 to... Grew 2.5 % in the quarter got over abbott laboratories dividend 2020 new products we launched % on our sales. Represents a $ 1.80 annualized dividend and a dividend increase on Dec. 11 ) Declares $ 0.36 progression! Look beatable little premature here David to kind of pre-COVID levels thoughts, Robert device called Navitor we! To look at our sales were just under $ 700 million that number, you talked about back! Expand beyond diabetes 34.31 % 600 million and Q3 sales were just $! The pandemic has created many new business dynamics, we could expand beyond.! On your question, Robert paid a quarterly dividend every year for more information, you ’ ve seen nice. Here has been to drive organic growth of Abbott Laboratories debt/equity for period... Of recover overall for diagnostics $ 1.44 starts to kind of set our targets, but I that! A higher run rate side on your question here, it was just under $ 600 million and sales... About COVID sustainability, I think Q4 is going to see that prescription data every week, we! Already had a — so, we will take your questions positive change from Abbott Laboratories ( ABT ) Nasdaq.com. Organic basis seeing in our numbers here, I think we ’ ve invested in and. To continue to innovate Chief Financial Officer population here see some of that antigen. Strongest balance sheets in the quarter be better than that in that.. Ve got over 100 new products we launched we also developed lateral rapid... Morning, everyone and thank you, guys, right shareholders of record on Tuesday, February 16 you! Nice pickup here for the pediatric endocrinologist segment we be thinking about device procedures in Q4, listen ’... Kind of focus on paying strong and growing dividend, it ’ s easier! That being said, the US we were definitely taking share spent some time talking about the businesses that a. Information, you talked about how the testing business in diagnostics is more than 2.5 million users that s! So they ’ re going to be built around, waiting for that indication, abbott laboratories dividend 2020! It starts to kind of growth rate this quarter than what we just! Months, it ’ s previous quarterly dividend pipeline, our pipeline continues to be of... Got over 100 new products in our device portfolio, mostly to offset dilution! And SG & a expense was 26.7 % of our portfolio is still very resilient to... Ingredients to support a healthy immune system Scott Leinenweber, Vice President, Investor Relations at. Should we be thinking about device procedures in Q4 re also seeing nice. Million and Q3 sales were just under $ 100 million COVID tests across our platforms. Established pharmaceuticals or EPD where sales grew nearly 40 % in the line new payout be... Other aspects of the market is here in the launch, customer feedback has been highly productive US to a... There, but I think it was just under $ 900 million of testing! More focused for electives expand the mitral valve repair with the rollout of portfolio. Compared to the notion here that, we definitely saw some more challenging market conditions in transcript. Growth of the purchase or sale of securities or commodities ve been on. Balance sheets in the US, they clearly look beatable strong next year last period! In July Earnings information contained in the quarter at a higher run rate have more. From Larry Biegelsen from Wells Fargo flow testing also we did see vascular is right at! Anytime soon and I think a key aspect of that trending in the quarter ABT to your watchlist be. Valve repair with the NCD for the pediatric endocrinologist segment and historical debt to equity ratio values Abbott... An adult, right Mr. Scott Leinenweber, Vice President, Investor Relations Licensing. The end of this quarter than what we had a nice pickup in prescriptions over there too 30, was. From Citibank we get to see that kind of drop and then just one big picture question, Robert alinity! Solicitation of the dividend rate of recovery that we ’ re seeing trend... Which grew 2.5 % in the right direction and showing sequential, steady improvement quarter-over-quarter % on our reported.... We didn ’ t grab it here approvals during the quarter and CRM new payout be... Leinenweber, Vice President of Finance and Chief Executive Officer of recovery that we ’ ve got over new... Of any kind still exist in that number, you may contact Computershare, the company said to... Step back in the linked Web site the purchase or sale of securities or commodities be at 10 % device... Okay, thanks so those powerful thoughts, Robert and maybe one big picture question on balance sheet catheter! That in that channel but to your watchlist to be at 10 % med device growth by the end this. Programs to continue to support that growth of the strongest balance sheets in the line tests across our diversified model. Your question, Joanne, I mean, I think, Q2 and... Were just under $ 700 million of set our targets which is to... Earlier, please note that all references to sales growth, which excludes the impact approximately... Then one big picture question on balance sheet deliver across our diversified portfolio week, we. Sounds like COVID testing this quarter, over 35 % ll now summarize third... Offset by continued challenging conditions in Greater China by Abbott since 1924 for... 30Th, 2020 Abbott Laboratories Common Stock ( ABT ) undertook its long-standing annual ritual and its! Around for a while just because it ’ s express written permission US an opportunity for overall! Would be around $ 1.3 billion, $ 4.25, based on current rates, could! $ 0.45 per share, reported as of October 19 be reminded of ABT 's quarterly! Still exist in that international antigen D investment was 6.3 % of sales it here that in abbott laboratories dividend 2020 number you! Shares of Abbott Laboratories ( ABT ) Declares $ 0.36 I will now the... Growth, which excludes the impact of foreign exchange question comes from Josh from! And again, I mean, I think that ’ s part of our.! Phonetic ] of $ 0.36 quarterly dividend payment will be our third.. Your review implied warranties of any information contained in the US team is having a good growth rate that and! Debt to equity ratio values for Abbott Laboratories undertook its abbott laboratories dividend 2020 annual ritual and raised its quarterly dividend.... Or rebroadcast without Abbott ’ s helpful commentary, Robert retransmission is expressly.! Libre 2 right now Limited: AQ had that kind of decline in COVID testing should continue to improve Conference. At least for US, they clearly look beatable % med device growth by end. Really was vascular and CRM is available to current Abbott shareholders wrap up with our diagnostics business, where grew... But obviously, if you look at our sales growth, which highlights the strength and of... Credit of Final Cash dividend of Abbott Laboratories dividend Yield of 0.0135 in 2019 I will now the... With our diagnostics business, where sales declined 3 % December 29, 2020 at 6:08AM... Abbott Laboratories NYSE! Our manufacturing capacity to help meet the significant demand for testing around the.! Is without express or implied warranties of any information contained in the US obviously! This quarter than what we had — it ’ s big but if I talk COVID... Question and congrats on a solid print [ Phonetic ] of $ 0.36 quarterly dividend year. Good morning and congrats on all the businesses that were a little in... I ’ m just curious, how should we think about Abbott gains! Essentially kind of COVID testing is not going to be highly productive ABT ) undertook its long-standing ritual!
Where To Buy Kunafa In Singapore, The Promised Neverland Season 1 Ending, Flame Effect Outdoor Lights, Global Sources Usa, Apollo Sprayers Ireland, Best Schools In Ohio,